Feature | February 07, 2014

Transcatheter Pump May Aid Heart Failure Patients

Procyrion Aortix Ventricular Assist Device Hemodynamic Support Heart Failure
February 7, 2014 — Start-up company Procyrion Inc. is developing a catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. The 6-mm diameter Aortix device is narrower than a pencil and is delivered via a catheter in a minimally invasive outpatient procedure lasting about 10 minutes.
 
Currently, long-term mechanical circulatory support (MCS) is limited to large ventricular assist devices (VADs). These devices are mainly used in patients with late stage heart failure (HF). Procyrion is developing a percutaneous intra-aortic micro-axial fluid entrainment pump called Aortix intended for long-term MCS in patients with earlier stage HF.
 
Aortix has been successfully tested with computer models, on the bench top in mock flow loops and in vivo in large animal HF studies. In three porcine experiments conducted last year, the pump was deployed in the thoracic aorta by standard cardiac catheterization techniques and was anchored with self-expanding struts. Acute cardiac dysfunction was induced by infusing esmolol continuously. Pump support increased cardiac output (+10.4 percent), stroke volume (+8.9 percent), and ejection fraction (+10.8 percent) while decreasing cardiac stroke work (-10.8 percent) and afterload (-22.7 percent). Pump support enhanced renal perfusion through sustained increases in both renal artery flow (+36.4 percent) and pressure (+73.6 percent).
 
In a porcine model of acute HF, the catheter-based intra-aortic fluid entrainment pump improved hemodynamics and renal perfusion. These results suggest the pump could improve HF outcomes and patients' quality of life by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion. The renal perfusion may help disrupt the cardiorenal syndrome cycle and improve HF treatment.
 
The company received the Commercialization award by the Gulf Coast Regional Center of Innovation and Commercialization in February 2013 and received a total of $1.5 million in assistance from the Texas Emerging Technology Fund.  
 
 
For more information: www.procyrion.com

Related Content

Feature | Business| April 28, 2016 | Dave Fornell
 
CABG, bypass surgery, heart failure, NHLBI study
News | Cardiovascular Surgery| April 25, 2016
Scientists have found that a greater number of patients with coronary artery disease may benefit from coronary artery...
News | Heart Failure| April 19, 2016
In one of the largest trials ever conducted of heart failure patients with reduced ejection fraction, the...
St. Jude Medical, SJM, MultiPoint Pacing, CRT, cardiac resynchronization therapy, U.S. launch
Technology | Cardiac Resynchronization Therapy Devices (CRT)| April 18, 2016
St. Jude Medical Inc. announced the U.S. launch and first U.S. implants of the Quadra Assura MP cardiac...
News | Heart Failure| April 15, 2016
April 15, 2016 — An investigational stem cell therapy derived from patients’ own blood marrow significantly improved
cardiofit, vagus nerve stimulation for heart failure, bio control medical

An illustration showing the implant of the Cardiofit device.

Feature | Heart Failure| April 15, 2016
April 15, 2016 — A new implantable medical device intended to help patients with heart failure by stimulating the vag
Edema Guard Monitor, RS MEDICAL
News | Heart Failure| April 15, 2016
April 15, 2015 — In patients with heart failure, use of an investigational device that monitors the accumulation of f
Abiomed, Impella, FDA approval, cardiogenic shock
Technology | Ventricular Assist Devices (VAD)| April 11, 2016
Abiomed Inc. announced that it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for its...
ixCELL-DCM trial, stem cell therapy, heart failure, ACC 2016, Amit Patel

Three-dimensional electrochemical mapping was used to target ixmyelocel-T cell therapy to damaged areas of hearts in patients with end-stage heart failure. Image courtesy of Matthew Brobeck.

News | Stem Cell Therapies| April 06, 2016
End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent...
CMS, Mapping Medicare Disparities Tool, MMD, healthcare quality
News | Analytics Software| March 29, 2016
The Centers for Medicare & Medicaid Services Office of Minority Health (CMS OMH) released a new interactive map to...
Overlay Init